Want to see BNBX full AI Analyst Report?
BNBX Stock Chart & Stats
$0.09
<$0.01(5.92%)
At close: 4:00 PM EDT
$0.09
<$0.01(5.92%)
Day’s Range― - ―
52-Week Range$0.07 - $7.15
Previous CloseN/A
Volume2.78K
Average Volume (3M)1.96M
Market Cap
$791.70K
Enterprise Value$4.91
Total Cash (Recent Filing)$949.09K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.67
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-39.93
Shares Outstanding7,197,228
10 Day Avg. Volume46,292
30 Day Avg. Volume1,955,224
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-82.5
Revenue Forecast (FY)$7.40M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Stronger EquityA near-zero debt load and a material equity increase materially reduce refinancing and solvency risk, giving management durable financial flexibility. This stronger capitalization supports runway and strategic options (asset monetization, selective investment) without immediate debt pressure.
Revenue Rebound & Profitable Unit OptionalityA large TTM revenue rebound signals improving top-line traction, while the profitable LineaRx DNA unit provides a monetizable asset and operational diversification. Together they create lasting optionality to fund operations or reduce cash burn if management executes on monetization.
Committed Preferred Financing Expands RunwayA structured preferred-stock financing with committed investors and seniority helps extend runway and funds strategic initiatives. The deal's senior status and guarantees from digital-asset subsidiaries materially improve near-term liquidity and permit time for value-creation actions.
Bears Say
Severe Cash BurnSustained multi-million dollar negative operating and free cash flow creates structural funding pressure, forcing recurring financings or asset sales. Over months this elevates dilution risk, constrains investments, and threatens continuity absent durable improvement or successful asset monetization.
Extremely Weak Profitability & MarginsVery large negative operating and net margins indicate the cost base is far out of line with current revenue, limiting operational leverage. Without structural cost reduction or meaningful scale, profitability is unlikely to normalize, undermining long-term return generation.
Liquidity & Governance DisruptionA forced transfer to OTCQB reduces market liquidity and access to a broad investor base, raising financing costs. Concurrent settlement and senior departures create governance and execution uncertainty during a strategic review, complicating monetization and operational turnaround efforts.
BNB Plus News
BNBX FAQ
What was BNB Plus’s price range in the past 12 months?
BNB Plus lowest stock price was $0.07 and its highest was $7.15 in the past 12 months.
What is BNB Plus’s market cap?
BNB Plus’s market cap is $791.70K.
When is BNB Plus’s upcoming earnings report date?
BNB Plus’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were BNB Plus’s earnings last quarter?
BNB Plus released its earnings results on May 07, 2026. The company reported -$0.685 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is BNB Plus overvalued?
According to Wall Street analysts BNB Plus’s price is currently Overvalued.
Does BNB Plus pay dividends?
BNB Plus does not currently pay dividends.
What is BNB Plus’s EPS estimate?
BNB Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BNB Plus have?
BNB Plus has 7,197,228 shares outstanding.
What happened to BNB Plus’s price movement after its last earnings report?
BNB Plus reported an EPS of -$0.685 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.99%.
Which hedge fund is a major shareholder of BNB Plus?
Currently, no hedge funds are holding shares in BNBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BNB Plus
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
―
Ownership Overview
2.34% Insiders
0.42% Mutual Funds
<0.01% Other Institutional Investors
97.23% Public Companies and
Individual Investors